Arcadia Biosciences Inc RKDA.OQ RKDA.O is expected to show a fall in quarterly revenue when it reports results on August 13 for the period ending June 30 2024
The Davis California-based company is expected to report a 33.4% decrease in revenue to $925 thousand from $1.39 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for Arcadia Biosciences Inc is for earnings of $1.55 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," "hold" and "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Arcadia Biosciences Inc is $9.00, above its last closing price of $2.66.
This summary was machine generated August 9 at 21:23 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)